SEC Filing Summary: Midatech Pharma PLC (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Midatech Pharma PLC, a foreign private issuer, for the month of October 2019. The report was submitted on October 2, 2019, and incorporates by reference a press release regarding corporate governance actions.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure of a specific corporate event rather than a financial performance update.
Material Changes
The material change disclosed in this filing is the award of stock options to a Director, as detailed in the attached press release dated October 2, 2019. No financial performance changes versus prior periods are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The sole focus is the notification of the option award to a Director.
Key Facts for Investor Verification
- The registrant is Midatech Pharma PLC, headquartered in Cardiff, United Kingdom.
- The filing discloses an "Award of Options to a Director" via a press release dated October 2, 2019.
- No financial statements or operational metrics are included in this specific Form 6-K.
- The report was signed by Stephen Stamp, Chief Financial Officer.